Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
4.47% $7.59
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 484.24 mill |
EPS: | -0.840 |
P/E: | -9.04 |
Earnings Date: | May 12, 2024 |
SharesOutstanding: | 63.80 mill |
Avg Daily Volume: | 0.606 mill |
RATING 2024-03-28 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Strong Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -9.04 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-1.54x |
Company: PE -9.04 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.483 (-93.64%) $-7.11 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 6.56 - 8.62 ( +/- 13.60%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-16 | Flynn James E | Buy | 1 430 206 | Common Stock |
2024-02-16 | Flynn James E | Buy | 1 430 206 | Common Stock |
2024-02-16 | Flynn James E | Buy | 1 430 205 | Common Stock |
2024-02-14 | Thomas Frank E | Buy | 2 000 | Common Stock |
2024-01-17 | Shankar Gopi | Buy | 135 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
100.00 |
Last 91 transactions |
Buy: 20 937 267 | Sell: 6 152 661 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $7.59 (4.47% ) |
Volume | 0.515 mill |
Avg. Vol. | 0.606 mill |
% of Avg. Vol | 84.92 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 9 - 11:45 | buy | $6.54 | N/A | Active |
---|
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.